NCT00280098已完成4 期
Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- PSA decline
研究概览
简要总结
Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced prostate cancer, without previous chemotherapy, progressing on hormonal treatment, performance status 1 to 2
排除标准
- •Other cytostatic treatment, other malignity, severe comorbidity
研究组 & 干预措施
single group
Experimental
干预措施: docetaxel (Drug)
结局指标
主要结局
PSA decline
时间窗: after each docetaxel administration and after the end of treatment
pain response
时间窗: after each docetaxel administration and after the end of treatment
side effects occurrence
时间窗: Throughout the study
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate CancerProstate CancerNCT00126230Gustave Roussy, Cancer Campus, Grand Paris55
已完成
2 期
Docetaxel in Treating Patients With Persistent or Recurrent Cervical CancerCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Cervical CarcinomaNCT00041093Gynecologic Oncology Group27
Unknown
2 期
Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCCHead and Neck Squamous Cell CarcinomaNCT02639858Samyang Biopharmaceuticals Corporation31
终止
1 期
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's LymphomaNon-Hodgkins LymphomaProstate CancerNCT00848601Astex Pharmaceuticals, Inc.14
已完成
1 期
A Study of Ramucirumab (IMC-1121B) in Participants With Breast CancerBreast CancerMetastatic Breast CancerNCT01256567Eli Lilly and Company7